Safety and Immune Response to FMPV-1
Primary Purpose
Colorectal Cancer
Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
FMPV-1
GM-CSF (as adjuvant)
Sponsored by
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring FMPV-1, Cancer-specific vaccine, Neoantigen, GM-CSF adjuvant
Eligibility Criteria
Inclusion Criteria:
- Healthy males
- Aged 18 to 55 years inclusive at the time of signing informed consent
- Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening
- Must provide written informed consent
- Must agree to adhere to the contraception requirements: male subjects who are sexually active with a partner of childbearing potential must use a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days (one cycle of spermatogenesis) after last vaccine administration.
Exclusion Criteria:
- Subjects who have received any investigational medicinal product in a clinical research study within the 90 days prior to Day 1 or within less than 5 elimination half-lives prior to Day 1, whichever is longer
- Subjects who are, or are immediate family members of, a study site or sponsor employee
- Subjects who have previously been administered investigational medicinal product in this study.
- Evidence of current SARS-CoV-2 infection
- History of any drug or alcohol abuse in the past 2 years
- Regular alcohol consumption defined as >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
- A confirmed positive alcohol breath test at screening or admission
- Current smokers and those who have smoked within the last 6 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
- Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 6 months
- Subjects with pregnant or lactating partners
- Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are not allowed.
- Confirmed positive drugs of abuse test result
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results
- History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- Presence or history of a clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
- Subjects currently receiving any agent with a known effect on the immune system within 90 days before first investigational medicinal product administration
- Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
- Subjects who are taking, or have taken, any prescribed or over-the-counter medications, herbal remedies or antihistamines (other than vitamin supplements and/or up to 4 g of paracetamol per day) in the 7 days before investigational medicinal product administration
- Subjects who have had a vaccine (including COVID-19 vaccine) within 28 days before first dose
- Subjects with tattoos or scars on the arms which may interfere with injection site assessments, as determined by the investigator or delegate at screening
Subjects with any other illnesses or medical conditions such as, but not limited to:
- Any infection that requires systemic treatment (any grade)
- Cardiac failure (any grade)
- Systemic and gastrointestinal inflammatory conditions
- Bone marrow dysplasia
- History of auto-immune disease
- History of adverse reactions to any vaccines
- History of adverse reactions to GM-CSF
- Subjects with any other malignancies within the last 3 years (except for adequately treated carcinoma of the cervix or basal or squamous cell skin cancer)
- Subjects planning to receive a yellow fever or other live (attenuated) vaccine during the course of study
- Subject has a first degree relative with a haematological malignancy
- Failure to satisfy the investigator of fitness to participate for any other reason
Sites / Locations
- Quotient Sciences
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
FMPV-1 vaccination
Arm Description
GM-CSF (0.03 mg) + FMPV-1 (0.15 mg/injection: low dose) administered as 2 separate intradermal injections. Total of 8 administrations intradermally; GM-CSF + FMPV-1 on 5 separate occasions and FMPV-1 (without GM-CSF) on 3 occasions for the DTH skin reactivity assessment.
Outcomes
Primary Outcome Measures
Delayed Type Hypersensitivity Skin Reactivity Test
DTH test performed on Days 3, 29 and 43 with response assessment on Days 8, 31 and 45. A positive DTH response will be recorded if the area of the skin reaction (redness and/or induration) at the injection site has an average diameter ≥5 mm 48 h after injection.
Proliferative T-cell Responses
Whole Blood Samples for Proliferative T-cell Responses taken on Days 1, 45, 57±1, 80±3, 6-month and 12-month follow-ups. Samples will be processed to isolate PBMCs for T-cell receptor analysis.
Summary of Adverse Events
An AE is any untoward medical occurrence in a subject that occurs either before dosing (referred to as a pre-dose AE) or once a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product. AEs will be monitored from the time the subject signs the ICF until after the 12-month follow-up visit.
Secondary Outcome Measures
Full Information
NCT ID
NCT05238558
First Posted
January 26, 2022
Last Updated
September 20, 2023
Sponsor
Hubro Therapeutics AS
Collaborators
Quotient Sciences
1. Study Identification
Unique Protocol Identification Number
NCT05238558
Brief Title
Safety and Immune Response to FMPV-1
Official Title
A Phase I Study of FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
January 31, 2022 (Actual)
Primary Completion Date
October 31, 2022 (Actual)
Study Completion Date
June 30, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hubro Therapeutics AS
Collaborators
Quotient Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.
Detailed Description
To date, there is no clinical experience with FMPV-1. This is the first clinical study with FMPV-1 in healthy volunteers to assess the safety and immunogenicity of FMPV-1 in man. The study population will include 16 healthy males in 2 cohorts (8 per cohort) to ensure data in a minimum of 14 subjects.
Up to two dose levels of FMPV-1 in conjunction with the adjuvant granulocyte macrophage colony stimulating factor (GM-CSF) will be assessed - the dose in Cohort 2 will depend on the safety and specific delayed type hypersensitivity (DTH) response data from Cohort 1. Each cohort will follow the same study design. Following preliminary screening procedures, subjects will be admitted in the morning on the day before initial dosing (Day -1). In Cohorts 1 and 2, subjects will receive FMPV-1 15 ± 5 min after GM-CSF on Days 1, 8, 15, 29 and 43 as an intradermal injection into the back of the upper arm. In Cohort 1, 8 subjects will receive GM-CSF (0.03 mg) + FMPV-1 (0.15 mg/injection: low dose) administered as 2 separate intradermal injections. In Cohort 2, 8 subjects will receive GM-CSF (0.03 mg) + FMPV-1 (either 0.15 or 0.3 mg/injection - dependent on Cohort 1 data) administered as 2 separate intradermal injections.
Sentinel dosing will be applied for both cohorts if different doses are used; if the same dose is to be used in both cohorts, sentinel dosing will not be applied in Cohort 2.
Adverse events and laboratory assessments will be the endpoints to assess the safety of GM-CSF/FMPV-1 vaccination. FMPV-1 specific DTH responses and FMPV-1-specific proliferative T-cell responses will be the endpoints to assess the FMPV-1 specific immune response. Subjects will receive a total of 8 administrations intradermally: GM-CSF + FMPV-1 on 5 separate occasions and FMPV-1 (without GM-CSF) on 3 occasions for the DTH skin reactivity assessment. The main part of the study will last for approximately 16 weeks, including screening, and subjects will return for follow-up visits after 6 months and 12 months. The overall estimated time from screening until the final follow-up visit is approximately 12 months. All adverse reactions will be collected until early withdrawal or discharge from the study after the 12-month follow-up visit.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer
Keywords
FMPV-1, Cancer-specific vaccine, Neoantigen, GM-CSF adjuvant
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
FMPV-1 vaccination
Arm Type
Experimental
Arm Description
GM-CSF (0.03 mg) + FMPV-1 (0.15 mg/injection: low dose) administered as 2 separate intradermal injections.
Total of 8 administrations intradermally; GM-CSF + FMPV-1 on 5 separate occasions and FMPV-1 (without GM-CSF) on 3 occasions for the DTH skin reactivity assessment.
Intervention Type
Biological
Intervention Name(s)
FMPV-1
Intervention Description
Intradermal administration
Intervention Type
Biological
Intervention Name(s)
GM-CSF (as adjuvant)
Intervention Description
Intradermal administration
Primary Outcome Measure Information:
Title
Delayed Type Hypersensitivity Skin Reactivity Test
Description
DTH test performed on Days 3, 29 and 43 with response assessment on Days 8, 31 and 45. A positive DTH response will be recorded if the area of the skin reaction (redness and/or induration) at the injection site has an average diameter ≥5 mm 48 h after injection.
Time Frame
45 days
Title
Proliferative T-cell Responses
Description
Whole Blood Samples for Proliferative T-cell Responses taken on Days 1, 45, 57±1, 80±3, 6-month and 12-month follow-ups. Samples will be processed to isolate PBMCs for T-cell receptor analysis.
Time Frame
12 months
Title
Summary of Adverse Events
Description
An AE is any untoward medical occurrence in a subject that occurs either before dosing (referred to as a pre-dose AE) or once a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product. AEs will be monitored from the time the subject signs the ICF until after the 12-month follow-up visit.
Time Frame
12 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy males
Aged 18 to 55 years inclusive at the time of signing informed consent
Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening
Must provide written informed consent
Must agree to adhere to the contraception requirements: male subjects who are sexually active with a partner of childbearing potential must use a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days (one cycle of spermatogenesis) after last vaccine administration.
Exclusion Criteria:
Subjects who have received any investigational medicinal product in a clinical research study within the 90 days prior to Day 1 or within less than 5 elimination half-lives prior to Day 1, whichever is longer
Subjects who are, or are immediate family members of, a study site or sponsor employee
Subjects who have previously been administered investigational medicinal product in this study.
Evidence of current SARS-CoV-2 infection
History of any drug or alcohol abuse in the past 2 years
Regular alcohol consumption defined as >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
A confirmed positive alcohol breath test at screening or admission
Current smokers and those who have smoked within the last 6 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 6 months
Subjects with pregnant or lactating partners
Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are not allowed.
Confirmed positive drugs of abuse test result
Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results
History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
Presence or history of a clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
Subjects currently receiving any agent with a known effect on the immune system within 90 days before first investigational medicinal product administration
Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
Subjects who are taking, or have taken, any prescribed or over-the-counter medications, herbal remedies or antihistamines (other than vitamin supplements and/or up to 4 g of paracetamol per day) in the 7 days before investigational medicinal product administration
Subjects who have had a vaccine (including COVID-19 vaccine) within 28 days before first dose
Subjects with tattoos or scars on the arms which may interfere with injection site assessments, as determined by the investigator or delegate at screening
Subjects with any other illnesses or medical conditions such as, but not limited to:
Any infection that requires systemic treatment (any grade)
Cardiac failure (any grade)
Systemic and gastrointestinal inflammatory conditions
Bone marrow dysplasia
History of auto-immune disease
History of adverse reactions to any vaccines
History of adverse reactions to GM-CSF
Subjects with any other malignancies within the last 3 years (except for adequately treated carcinoma of the cervix or basal or squamous cell skin cancer)
Subjects planning to receive a yellow fever or other live (attenuated) vaccine during the course of study
Subject has a first degree relative with a haematological malignancy
Failure to satisfy the investigator of fitness to participate for any other reason
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nand Singh
Organizational Affiliation
Quotient Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Quotient Sciences
City
Nottingham
ZIP/Postal Code
NG11 6JS
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Safety and Immune Response to FMPV-1
We'll reach out to this number within 24 hrs